Evidence map›Paper›PMID 41476194›Full record

ArticleBMC endocrine disorders2025

New sights of tumor-specific growth factor (TSGF) in T2DM patients with coronary artery disease.

Ya Fang, Zaifei Yin, Yuzhu Zhu, Minghui Shao, Hong Sun

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ya FangDepartment of Endocrinology and Metabolism, The Fourth Affiliated Hospital of Soochow University, Suzhou Dushu Lake Hospital, Medical Center of Soochow University, Suzhou, Jiangsu, 215123, China.
Zaifei YinDepartment of Endocrinology and Metabolism, The Fourth Affiliated Hospital of Soochow University, Suzhou Dushu Lake Hospital, Medical Center of Soochow University, Suzhou, Jiangsu, 215123, China.
Yuzhu ZhuDepartment of Endocrinology and Metabolism, The Fourth Affiliated Hospital of Soochow University, Suzhou Dushu Lake Hospital, Medical Center of Soochow University, Suzhou, Jiangsu, 215123, China.
Minghui ShaoClinical Medicine School of Soochow University, Suzhou, Jiangsu, 215031, China.
Hong SunDepartment of Endocrinology and Metabolism, The Fourth Affiliated Hospital of Soochow University, Suzhou Dushu Lake Hospital, Medical Center of Soochow University, Suzhou, Jiangsu, 215123, China. sunhong_611@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsTo investigate the correlation between tumor-specific growth factor (TSGF) and the presence of coronary artery disease (CAD) in individuals with type 2 diabetes mellitus (T2DM). METHODS AND

resultsData from a total of 223 subjects with T2DM were cross-sectionally analyzed. Serum TSGF concentrations were measured using an enzyme-linked immunosorbent assay (ELISA) in both CAD-positive and CAD-negative subjects. Logistic regression analysis was used to assess the association between TSGF and CAD, while controlling for major risk factors. The predictive power of TSGF for CAD was determined through receiver operating characteristic (ROC) curve analysis. Among the 223 subjects, 136 had no CAD and 87 exhibited clinically significant CAD. The median serum TSGF level was significantly higher in the CAD group (66.8 U/ml) compared to the non-CAD group (59.4 U/ml; p < 0.001). Binary logistic regression, adjusted for major risk factors, confirmed a strong association between TSGF and CAD (p < 0.001). The ROC analysis identified an optimal TSGF cutoff of 62.5 U/ml, with a sensitivity of 70.1% and a specificity of 64% in predicting CAD in T2DM patients.

conclusionThe results showed a significant increase in TSGF levels in CAD patients with T2DM. These findings suggest that TSGF could be a promising biomarker for CAD diagnosis in T2DM patients, and further research is warranted to evaluate its clinical utility. CLINICAL TRIAL NUMBER: Not applicable.

Indexed as

BiomarkersCoronary Artery DiseaseDiabetes Mellitus, Type 2AgedCross-Sectional StudiesFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisRisk FactorsROC CurveBiomarkersAtherosclerosisCoronary artery diseaseCross-sectional studyTSGFType 2 diabetes mellitus

Identifiers

PMID41476194
PMCPMC12866437

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.